A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Clinical trial NCT00874731 · COMPLETED

Trial details

NCT number: NCT00874731
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic or Locally Advanced Cancer

Start date: 2009-04-28
Primary completion: 2009-10-30
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.